Market Overview

Vetr Crowd Upgrades Bluebird After Trump Presser

Related BLUE
31 Stocks Moving In Monday's Mid-Day Session
20 Stocks Moving In Monday's Pre-Market Session
Bluebird bio's Lenti-D a Breakthrough Therapy for rare neurological disorder; shares up 2% (Seeking Alpha)

On Wednesday, the Vetr crowd upgraded their rating for bluebird bio Inc (NASDAQ: BLUE), from 2.5 Stars (Sell) issued two days ago, to 3.5 Stars (Buy). Crowd sentiment for the stock is generally cautious, with 66 percent of Vetr user ratings bearish.

The gene therapy company experienced the same drop many biotech firms experienced in the wake of President-elect Donald Trump's first press conference following his election win in November. The sector saw an immediate selloff following the President-elect's comment about the cost of consumer drug prices.

Shares of bluebird bio fell over 5 percent to $64.70 immediately following the remark made around noon on January 11. The stock bounced back slightly as traders capitalized on the market's reaction. The stock still finished the day down at $65.05.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for the stock is up at $69.48, which is well below the average analyst target price of $88.77. Less than 2 percent of Vetr users are holding BLUE in their watch lists.

Latest Ratings for BLUE

May 2018BMO CapitalMaintainsOutperformOutperform
Mar 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Mar 2018Janney CapitalInitiates Coverage OnNeutral

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Crowdsourcing Analyst Ratings


Related Articles (BLUE)

View Comments and Join the Discussion!